Surgeon General releases a Call to Action on Hypertension

The office of the Surgeon General releases a call to action recommending that hypertension control become a national public health priority, optimizing patient care, and building a community to help control high blood pressure. Progress made in controlling hypertension “is slipping away from us”, said, U.S. Surgeon General Jerome M. Adams, MD, MPH. This leaves…

Read More

Esperion Announces Commercial Availability of NEXLIZET™ (bempedoic acid and ezetimibe) Tablets and Ushers in New Era of Oral Combination Medicine for LDL-Cholesterol Lowering

– First-Ever Non-Statin Combination Medicine, Providing 38 Percent Mean LDL-C Lowering –– Esperion Aims to Set New Industry Standard by Pricing NEXLIZET for Patient Affordability and Access with Minimal to No Paperwork Requirements for Health Care Providers –– Launch Date Accelerated by One Month at Health Care Providers Request – ANN ARBOR, Mich., June 04, 2020 (GLOBE NEWSWIRE)…

Read More

ASPC Health and Wellbeing for All Statement

The past few months we have faced unprecedented times across the globe. The recent events, including ongoing episodes of racism and violence, underscore the urgency for us to prioritize inclusion, amplify marginalized voices, and continue to shine a light on cardiovascular health issues that affect so many. Cardiovascular disease does not discriminate by race, color,…

Read More

Nexletol™ (Bempedoic Acid), a New LDL-C Lowering Therapy, Now Available in U.S. Pharmacies

Esperion has announced that NEXLETOL™ (bempedoic acid) is now available in pharmacies in the United States. NEXLETOL is an oral, once-daily, tablet indicated as an adjunct to diet and maximally tolerated statin for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C. To…

Read More